Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000313143
$117.11
-0.93% · delayed ~15 min
Last price from Oct 21, 2026
$5.30B market value
From HAEMONETICS CORP's FY2026 10-K, filed May 20, 2026 · read the filing
HAEMONETICS makes medical devices and equipment. It took in $1.33B last year, which makes it a mid-sized company. Of every dollar it sells, about 7 cents is left as profit.
The financial picture is led by accounting, with profitability and debt worth watching, while growth remain weak.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From HAEMONETICS CORP's FY2026 annual filing · share price scored separately
Largest year-over-year changes in FY2026
Profit
$167.7M → $97.3M
Free cash flow
$142.4M → $260.4M
Operating income
$221.8M → $156.7M
Gross margin
55.0% → 59.0%
Measured against FY2025, from the 10-K filed May 20, 2026
Deteriorated: -42.0%
$167.7M to $97.3MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
HAE fell 0.93% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is 2.5 points below its sector and in line with the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 8% a year for the next 10 years. Over the last 10 years it grew by about 30% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 7 cents of every dollar of sales as profit, earning $97.3M last year.
No. Sales shrank 2.0% last year.
Manageable, but notable. Clearing its debt would take about 3.3 years of cash flow. For every $1 it owes, it owns $1.50 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2026 annual filing
Last year it earned $97.3M and generated $293.2M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202610-K · May 20, 2026Filing for FY2026 | FY202510-K · May 21, 2025Filing for FY2025 | FY202410-K · May 20, 2026Filing for FY2024 | FY202310-K · May 21, 2025Filing for FY2023 | FY202210-K · May 20, 2024Filing for FY2022 | ChangeFY2026 vs FY2025 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $1.33B | $1.36B | $1.31B | $1.17B | $993.2M | −2.0% |
| Cost of revenue | $546.4M | $611.9M | $617.5M | $553.6M | $487.7M | −10.7% |
| Gross profit | $787.6M | $749.0M | $691.5M | $615.1M | $505.5M | +5.2% |
| Gross marginGross profit ÷ revenueWhat is this? | 59.0% | 55.0% | 52.8% | 52.6% | 50.9% | +4.0 pts |
| Selling, general and administrative | $442.4M | $436.8M | $429.8M | $376.7M | $340.1M | +1.3% |
| Operating income | $156.7M | $221.8M | $164.9M | $156.0M | $80.8M | −29.3% |
| Operating marginOperating income ÷ revenueWhat is this? | 11.7% | 16.3% | 12.6% | 13.4% | 8.1% | −4.6 pts |
| Interest expense | $19.3M | $35.9M | $19.5M | $13.0M | $5.8M | −46.2% |
| Income before tax | $128.0M | $212.1M | $151.9M | $141.4M | $63.6M | −39.6% |
| Net income | $97.3M | $167.7M | $117.6M | $115.4M | $43.4M | −42.0% |
| Net marginNet income ÷ revenueWhat is this? | 7.3% | 12.3% | 9.0% | 9.9% | 4.4% | −5.0 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $2.15 | $3.48 | $2.31 | $2.29 | $0.8484 | −38.2% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| HAEHAEMONETICS CORP · this page | 6.0/10 | 7/9 | -2.0% | 7.3% |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Was granted or awarded shares — 2,538 shares
Holds 27,519 shares after this filing.
Was granted or awarded shares — 2,538 shares
Holds 9,664 shares after this filing.
Was granted or awarded shares — 2,538 shares
Holds 17,932 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Made a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingWrite down why you are following HAEMONETICS CORP, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 36 subsidiaries named in its 10-K, incorporated across 26 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from HAE's 10-K for fiscal year 2026 (period ending 2026-03-28, filed May 20, 2026), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2026 | 6.0 | 7/9 | 10-K, filed May 20, 2026 |
| FY2025 | 8.0 | 6/9 | 10-K, filed May 21, 2025 |
| FY2024 | 7.0 | 7/9 | 10-K, filed May 20, 2024 |
| FY2023 | 9.0 | 8/9 | 10-K, filed May 22, 2023 |
| FY2022 | 6.0 | 7/9 | 10-K, filed May 25, 2022 |
| FY2021 | 5.0 | 6/9 | 10-K, filed May 26, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
7 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
3.20
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.82
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2026 filing as filed with the SEC.
Improved: +82.8%
$142.4M to $260.4MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: -29.3%
$221.8M to $156.7MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +4.0 pts
55.0% to 59.0%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: −4.5 pts
16.3% to 11.7%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −5.0 pts
12.3% to 7.3%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -38.2%
$3.48 to $2.15Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: +32.4%
$921.2M to $1.22BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Deteriorated: -20.0%
$306.8M to $245.4MSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -6.1%
48.2M to 45.3MSignificant
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Changed: -16.5%
$39.3M to $32.8MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Improved: +5.2%
$749.0M to $787.6MNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Q1 FY2027 against Q1 FY2026, from the 10-Q filed Aug 6, 2026 — read it.
Improved: +225.6%
$13.6M to $44.4MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Changed: +110.6%
$3.8M to $7.9MCritical
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Deteriorated: +27.0%
$920.8M to $1.17BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Deteriorated: -23.7%
$292.9M to $223.4MSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -5.6%
48.2M to 45.5MSignificant
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Improved: +5.6%
$321.4M to $339.4MNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +5.5%
$192.2M to $202.8MNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +6.7%
$53.9M to $57.5MNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
1 other measure barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 6% and 10%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 15 analysts covering this company, as of . Their views, not this site's.
Of 15 analysts publishing on this company, 6 say strong buy, 6 say buy and 3 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 6.7% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 35.2x — a high multiple relative to the current trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 54.46x |
| 2.01x |
| ALGNALIGN TECHNOLOGY INC | 8.7/10 | 6/8 | 0.9% | 10.2% | 27.04x | 0.54x |
|---|
| Median of peers | 8.7/10 | — | 0.9% | 10.2% | 27.04x | 0.54x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Was granted or awarded shares — 2,538 shares
Holds 15,471 shares after this filing.
Was granted or awarded shares — 2,538 shares
Holds 27,295 shares after this filing.
Was granted or awarded shares — 2,538 shares
Holds 19,410 shares after this filing.
Was granted or awarded shares — 2,538 shares
Holds 21,911 shares after this filing.
Was granted or awarded shares — 2,538 shares
Holds 2,538 shares after this filing.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Quarterly report for Q1 FY2027
Revenue +5.6% · Free cash flow +225.6% · Capital spending +110.6% — against Q1 FY2026
Published results
Read the filingHad a director or senior officer leave or join · Held a shareholder vote
Read the filingProxy statement for a shareholder meeting
Read the filingMade a Regulation FD disclosure
Read the filingAnnual report for FY2026
Operating margin −4.5 pts · Profit -42.0% · Free cash flow +82.8% — against FY2025
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingMade a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2026
Operating margin +2.9 pts · Profit +19.3% · Gross margin +4.2 pts — against Q3 FY2025
Read the filingPublished results
Read the filingReported another event
Read the filingQuarterly report for Q2 FY2026
Revenue -5.3% · Operating margin +2.9 pts · Gross margin +5.3 pts — against Q2 FY2025
Read the filingPublished results
Read the filingQuarterly report for Q1 FY2026
Operating margin +4.9 pts · Free cash flow turned positive · Operating income +35.5% — against Q1 FY2025
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingSource: Exhibit 21 of the 10-K filed 2026-05-20. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Haemonetics Consensus Price Target Raised 24.88% to $145.63
Fintel ·
Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?
Yahoo ·
Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line
Yahoo ·
Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
Yahoo ·
Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures
Benzinga ·
1 Surging Healthcare Stock Worth Your Attention and 2 We Turn Down
Yahoo ·
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
Yahoo ·
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Yahoo ·
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140
Benzinga ·
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140
Benzinga ·
Haemonetics: CSL Plasma Improves The Outlook, Not The Entry Point (Rating Downgrade)
SeekingAlpha ·
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Yahoo ·
Primary sources and further research